During the 14-week placebo-controlled period in Trial 2, the most common reported adverse reactions in IMCIVREE-treated patients when compared to placebo-treated patients were hyperpigmentation disorders (67% vs 0%, respectively) and vomiting (11% vs 0%, respectively)
Mechanisms underlying cardiac protection include enhanced coronary angiogenesis, antioxidant effects reducing oxidative damage, anti-inflammatory modulation limiting inflammatory cell infiltration, and direct cardiomyocyte protection
Currently, there are no large-scale clinical trials specifically studying retatrutide and sugar cravings elimination together
These findings were confirmed by clonogenic assays, which demonstrated a significant reduction in the surviving fraction of MT treated cells (Fig
Bordeaux and ANR (Grant ANR-15-CE07-0010) is also gratefully acknowledged